Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HYPERSENSITIVITY AND ADVERSE REACTIONS ASSOCIATED WITH THE USE OF NEWER INTRANASAL CORTICOSTEROIDS FOR ALLERGIC RHINITIS
Autore:
QUINTILIANI R;
Indirizzi:
UNIV CONNECTICUT,HARTFORD HOSP,SCH MED,DEPT INFECT DIS & ALLERGY IMMUNOL,80 SEYMOUR ST,POB 5037 HARTFORD CT 06102
Titolo Testata:
Current therapeutic research
fascicolo: 7, volume: 57, anno: 1996,
pagine: 478 - 488
SICI:
0011-393X(1996)57:7<478:HAARAW>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
DAILY FLUTICASONE PROPIONATE; CONTACT ALLERGY; NASAL SPRAY; TOPICAL CORTICOSTEROIDS; CROSS-REACTIVITY; BUDESONIDE; DERMATITIS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
R. Quintiliani, "HYPERSENSITIVITY AND ADVERSE REACTIONS ASSOCIATED WITH THE USE OF NEWER INTRANASAL CORTICOSTEROIDS FOR ALLERGIC RHINITIS", Current therapeutic research, 57(7), 1996, pp. 478-488

Abstract

Reports of adverse events associated with two intranasal cortocosteroids, budesonide and fluticasone propionate, may make these products less desirable to physicians and patients. Ten cases of contact allergicreactions to intranasal budesonide have been reported. Many of these cases are characterized by perinasal eczema, often with vesicles, and edema as the initial symptoms. Lesions sometimes spread to the upper lip, cheeks, and eyelids. These results may be related to the more widely known findings that topically applied budesonide can cause contact dermatitis. For fluticasone propionate, analysis of data concerning adverse events from the Spontaneous Reporting System of the US Food and Drug Administration Division of Epidemiology and Surveillance revealedthat in the first 5 months since it was introduced into the United States on January 1, 1995, 46 patients reported 89 adverse events suspected to be caused by fluticasone propionate intranasal spray. Central nervous system symptoms occurred in 45.7%, cardiac symptoms in 28.0%, dermatologic symptoms in 39.0%, and epistaxis in 6.5% of the reported cases. These numbers may underestimate the problem, since no cases reported by the drug manufacturer had as yet been included. These results suggest safety issues may differentiate budesonide and fluticasone propionate from other intranasal corticosteroids such as beclomethasone dipropionate.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 23:05:13